Literature DB >> 22172047

Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.

Masaaki Watanabe1, Sumie Ogasawara, Akihiko Takahashi, Juichi Takada, Yoshiaki Tanaka, Yusuke Okuwaki, Tsutomu Minamino, Hisashi Hidaka, Takahide Nakazawa, Akitaka Shibuya, Wasaburo Koizumi.   

Abstract

A 62-year-old male treated with pegylated interferon α-2b plus ribavirin for chronic hepatitis C complained of sudden painless decreased visual acuity. This patient was diagnosed as having simultaneous occlusions of the branch retinal artery and central retinal vein, although he had no history of major risk factors for retinal vessel (artery and vein) occlusion. Unfortunately, visual acuity did not completely recover. Furthermore, the patient was heterozygous for interleukin (IL) 28B genetic polymorphisms. The etiology of interferon-associated retinal vessel occlusion is not yet clear. However, a review based on previous case reports suggested that some factors including ribavirin might act as a risk or cause of retinal vessel occlusion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22172047     DOI: 10.3109/15569527.2011.641197

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  3 in total

1.  Concurrent branch retinal artery occlusion in central retinal vein occlusion: 3 cases reports and literature review.

Authors:  Neha Goel
Journal:  Saudi J Ophthalmol       Date:  2021-02-27

Review 2.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

3.  Structural evaluation of the peritubular sheath of rat's testes after administration of ribavirin: A possible impact on the testicular function.

Authors:  Shaima M Almasry; Zeinab A Hassan; Wael M Elsaed; Yasser M Elbastawisy
Journal:  Int J Immunopathol Pharmacol       Date:  2017-08-11       Impact factor: 3.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.